According to filings with the U.S. Securities and Exchange Commission, Mitosense is raising up to $1,930,661.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Brent Segal played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Mitosense
MitoSense, Inc. is a research and development company in the field of securing development of treatments for neurodegenerative diseases. With exclusively licensed technology to replenish the mitochondria in humans using Mitochondria Organelle Transplantation (MOT), the company, through its U.S. based research partner is initially focusing its efforts on treating ALS. MOT may impact research for patients with Alzheimers, Parkinsons, Huntingtons and other neurodegenerative diseases, none of which have a cure. MitoSense uses a proprietary (patent pending) technique to replenish mitochondria to treat ALS. The technique has the potential to treat a wide range of indications including Alzheimers, Parkinsons, Huntingtons, Multiple Sclerosis and other neurodegenerative diseases. With experienced leadership in business, government, research, and medical, we have brought together a multidisciplinary team to help in the fight. Our team approach brings the distinct possibility of improving conditions in ALS patients and those with other neurodegenerative diseases. MitoSense began with the work of Dr. Robert Elliott, MD, PhD and continues in his memoriam.

To learn more about Mitosense, visit http://www.mitosenseinc.com/

Contact:
Brent Segal, Chief Executive Officer
781-832-0227

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.